ME02529B - Fuzionisana triciklična j edinjenja kao inhibitori raf kinaze - Google Patents
Fuzionisana triciklična j edinjenja kao inhibitori raf kinazeInfo
- Publication number
- ME02529B ME02529B MEP-2016-172A MEP17216A ME02529B ME 02529 B ME02529 B ME 02529B ME P17216 A MEP17216 A ME P17216A ME 02529 B ME02529 B ME 02529B
- Authority
- ME
- Montenegro
- Prior art keywords
- heterocyclyl
- alkyl
- heteroaryl
- cycloalkyl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 102000009929 raf Kinases Human genes 0.000 title claims 3
- 108010077182 raf Kinases Proteins 0.000 title claims 3
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 40
- 125000000623 heterocyclic group Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 25
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000001188 haloalkyl group Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 101150020251 NR13 gene Proteins 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 alkinil Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001952 enzyme assay Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085146 WO2013097224A1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
| EP11879096.3A EP2797888B1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02529B true ME02529B (me) | 2017-02-20 |
Family
ID=48696279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-172A ME02529B (me) | 2011-12-31 | 2011-12-31 | Fuzionisana triciklična j edinjenja kao inhibitori raf kinaze |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9273046B2 (index.php) |
| EP (2) | EP2797888B1 (index.php) |
| JP (1) | JP5868521B2 (index.php) |
| KR (1) | KR101713391B1 (index.php) |
| CN (1) | CN103596926B (index.php) |
| AU (1) | AU2011384857B2 (index.php) |
| BR (1) | BR112014013108B1 (index.php) |
| CA (1) | CA2856347C (index.php) |
| CY (1) | CY1118226T1 (index.php) |
| DK (1) | DK2797888T3 (index.php) |
| EA (1) | EA025597B1 (index.php) |
| ES (1) | ES2588775T3 (index.php) |
| HR (1) | HRP20160641T1 (index.php) |
| HU (1) | HUE029656T2 (index.php) |
| IL (1) | IL233364A (index.php) |
| IN (1) | IN2014DN06166A (index.php) |
| LT (1) | LT2797888T (index.php) |
| ME (1) | ME02529B (index.php) |
| MX (1) | MX352617B (index.php) |
| NZ (1) | NZ624068A (index.php) |
| PL (1) | PL2797888T3 (index.php) |
| PT (1) | PT2797888T (index.php) |
| RS (1) | RS55196B1 (index.php) |
| SG (1) | SG11201401725SA (index.php) |
| SI (1) | SI2797888T1 (index.php) |
| SM (1) | SMT201600302B (index.php) |
| WO (1) | WO2013097224A1 (index.php) |
| ZA (1) | ZA201405555B (index.php) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5868521B2 (ja) | 2011-12-31 | 2016-02-24 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| JP6380861B2 (ja) * | 2013-06-28 | 2018-08-29 | ベイジーン リミテッド | Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| GB201416186D0 (en) | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| CN113307805A (zh) | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| JP6175519B2 (ja) * | 2016-01-04 | 2017-08-09 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| JP6993056B2 (ja) * | 2016-07-05 | 2022-02-15 | ベイジーン リミテッド | 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ |
| HUE064609T2 (hu) | 2016-12-01 | 2024-04-28 | Arvinas Operations Inc | Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US10723717B2 (en) * | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| JP2020506922A (ja) | 2017-01-31 | 2020-03-05 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| BR112022003490A2 (pt) | 2019-08-26 | 2022-05-24 | Arvinas Operations Inc | Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida |
| CR20220353A (es) | 2019-12-19 | 2022-10-20 | Arvinas Operations Inc | Compuestos y métodos para la degradación dirigida del receptor de andrógenos |
| US11858930B2 (en) | 2020-07-28 | 2024-01-02 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic RAF inhibitors and methods for use thereof |
| JP2023539663A (ja) | 2020-08-28 | 2023-09-15 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| IL301155A (en) | 2020-09-14 | 2023-05-01 | Arvinas Operations Inc | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| MX2023007670A (es) * | 2020-12-29 | 2023-07-07 | Txinno Bioscience Inc | Nuevo derivado de naftiridinona que tiene actividad inhibidora contra la ectonucleotido pirofosfatasa -fosfodiesterasa y uso del mismo. |
| EP4404935A4 (en) * | 2021-09-21 | 2025-07-16 | Merck Sharp & Dohme Llc | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS |
| WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| WO2023212071A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Combination and the use thereof |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068773A1 (en) | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
| AU2005316668B2 (en) | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| WO2006066913A2 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| EP1885723A2 (en) | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| WO2006125101A2 (en) | 2005-05-20 | 2006-11-23 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2007002325A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
| KR20080052630A (ko) | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Ｒａｆ 억제제 화합물 및 그의 사용 방법 |
| KR20080074220A (ko) * | 2005-12-08 | 2008-08-12 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 키나아제 억제 활성을 갖는 비시클릭 화합물 |
| CA2651153C (en) * | 2006-05-15 | 2014-04-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| AU2007287319A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as GSK-3 inhibitors |
| BRPI0716477A2 (pt) | 2006-09-06 | 2014-03-18 | Hoffmann La Roche | Derivados heteroarila como inibidores de quinase protéica |
| US20080064729A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| WO2008137770A1 (en) * | 2007-05-04 | 2008-11-13 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| JP5868521B2 (ja) | 2011-12-31 | 2016-02-24 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| CN113307805A (zh) | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
-
2011
- 2011-12-31 JP JP2014549294A patent/JP5868521B2/ja active Active
- 2011-12-31 SI SI201130852A patent/SI2797888T1/sl unknown
- 2011-12-31 EP EP11879096.3A patent/EP2797888B1/en active Active
- 2011-12-31 KR KR1020147018101A patent/KR101713391B1/ko active Active
- 2011-12-31 LT LTEP11879096.3T patent/LT2797888T/lt unknown
- 2011-12-31 DK DK11879096.3T patent/DK2797888T3/en active
- 2011-12-31 AU AU2011384857A patent/AU2011384857B2/en active Active
- 2011-12-31 ME MEP-2016-172A patent/ME02529B/me unknown
- 2011-12-31 SG SG11201401725SA patent/SG11201401725SA/en unknown
- 2011-12-31 NZ NZ624068A patent/NZ624068A/en unknown
- 2011-12-31 PL PL11879096.3T patent/PL2797888T3/pl unknown
- 2011-12-31 HR HRP20160641TT patent/HRP20160641T1/hr unknown
- 2011-12-31 IN IN6166DEN2014 patent/IN2014DN06166A/en unknown
- 2011-12-31 HU HUE11879096A patent/HUE029656T2/en unknown
- 2011-12-31 BR BR112014013108-2A patent/BR112014013108B1/pt active IP Right Grant
- 2011-12-31 CN CN201180069798.XA patent/CN103596926B/zh active Active
- 2011-12-31 MX MX2014007829A patent/MX352617B/es active IP Right Grant
- 2011-12-31 PT PT118790963T patent/PT2797888T/pt unknown
- 2011-12-31 CA CA2856347A patent/CA2856347C/en active Active
- 2011-12-31 EP EP16167542.6A patent/EP3124472B1/en active Active
- 2011-12-31 ES ES11879096.3T patent/ES2588775T3/es active Active
- 2011-12-31 US US14/369,379 patent/US9273046B2/en active Active
- 2011-12-31 WO PCT/CN2011/085146 patent/WO2013097224A1/en not_active Ceased
- 2011-12-31 EA EA201491305A patent/EA025597B1/ru not_active IP Right Cessation
- 2011-12-31 RS RS20160713A patent/RS55196B1/sr unknown
-
2014
- 2014-06-25 IL IL233364A patent/IL233364A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05555A patent/ZA201405555B/en unknown
-
2016
- 2016-01-22 US US15/004,311 patent/US9895376B2/en active Active
- 2016-09-05 CY CY20161100869T patent/CY1118226T1/el unknown
- 2016-09-06 SM SM201600302T patent/SMT201600302B/it unknown
-
2018
- 2018-01-29 US US15/882,064 patent/US10576087B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02529B (me) | Fuzionisana triciklična j edinjenja kao inhibitori raf kinaze | |
| HRP20240300T1 (hr) | Spoj [1,2,4]triazolo[1,5-a]piridina kao inhibitor jak i njegova primjena | |
| ME02855B (me) | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI | |
| HRP20170217T1 (hr) | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| HRP20221112T1 (hr) | Derivati benzodiazepina kao inhibitori rsv | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| UA95632C2 (en) | Pyrrolopyrimidine compounds and their uses | |
| ME00876B (me) | 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati | |
| HRP20130942T1 (hr) | Aminodiazepini kao modulatori toll-u sliäśnih receptora | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| AU2023241329A1 (en) | Psychotropic agents and uses thereof | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| JP2012528194A (ja) | Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物 | |
| NL2000373C2 (nl) | Antibacteriële middelen. | |
| HRP20191525T1 (hr) | Inhibitori replikacije virusa influence | |
| RU2008141239A (ru) | Соединения тетрагидропиридотиенопиримидина и способы их применения | |
| JP2016513108A5 (ja) | 治療用化合物 | |
| JP2016512225A (ja) | アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体 | |
| HRP20140409T1 (hr) | Derivat imidazola sa strukturom prolinskog prstena | |
| IE64247B1 (en) | Carbamic acid ester of substituted 7-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepines |